A study to evaluate the efficacy and tolerability of PCSK9 inhibitors (Alirocumab and Evolocumab) in the current clinical practice in real-world settings
Latest Information Update: 29 Oct 2020
At a glance
- Drugs Alirocumab (Primary) ; Evolocumab (Primary)
- Indications Cardiovascular disorders; Hypercholesterolaemia; Hyperlipidaemia
- Focus Adverse reactions; Therapeutic Use
- 29 Oct 2020 New trial record
- 01 Sep 2020 Results presented at the ESC Congress 2020 - Annual Congress of the European Society of Cardiology